The interaction between the liver and the heart;Die Interaktion zwischen Leber und Herz

Zeitschrift fur Herz-, Thorax- und Gefasschirurgie

Volumn 24, Issue 6, 2010, Pages 334-340

  Kneiseler, G ^a   Herzer, K ^a   Marggraf, G ^a   Gerken, G ^a   Canbay, A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

glutamyltransferase; Brain natriuretic peptide; Heart failure; Liver cirrhosis; Troponin I

Indexed keywords

EID: 78650496499     PISSN: 09309225     EISSN: 14351277     Source Type: Journal    
DOI: 10.1007/s00398-010-0803-0     Document Type: Article

References (74)

1. Renz-Polster H, Krautzig S, Braun J (2004) Basislehrbuch Innere Medizin. 3. Aufl. Urban & Fischer Verlag, München.
2. Canbay A, Gerken G (2010) Die Leber in der Intensivmedizin. Aesopus Verlag e. K., Linkenheim-Hochstetten.
3. Kowalski HJ, Abelmann WH (1953) The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 32(10): 1025-1033.
4. Wong F (2009) Cirrhotic cardiomyopathy. Hepatol Int 3(1): 294-304.
5. Abelmann WH (1994) Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 20(5): 1356-1358.
6. Moller S, Henriksen JH (2008) Cardiovascular complications of cirrhosis. Gut 57(2): 268-278.
7. Wong F, Girgrah N, Graba J et al (2001) The cardiac response to exercise in cirrhosis. Gut 49(2): 268-275.
8. Grose RD, Nolan J, Dillon JF et al (1995) Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 22(3): 326-332.
9. Torregrosa M, Aguade S, Dos L et al (2005) Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 42(1): 68-74.
10. Pozzi M, Carugo S, Boari G et al (1997) Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 26(5): 1131-1137.
11. Henriksen JH, Fuglsang S, Bendtsen F et al (2002) Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 36(4): 513-520.
12. Bernardi M, Calandra S, Colantoni A et al (1998) QT interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27(1): 28-34.
13. Kosar F, Ates F, Sahin I et al (2007) QT interval analysis in patients with chronic liver disease: a prospective study. Angiology 58(2): 218-224.
14. Mohamed R, Forsey PR, Davies MK, Neuberger JM (1996) Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 23(5): 1128-1134.
15. Wu TT, Yuan A, Chen CY et al (2004) Cardiac troponin I levels are a risk factor for mortality and multiple organ failure in noncardiac critically ill patients and have an additive effect to the APACHE II score in outcome prediction. Shock 22(2): 95-101.
16. Pham MX, Whooley MA, Evans GT Jr et al (2004) Prognostic value of low-level cardiac troponin-I elevations in patients without definite acute coronary syndromes. Am Heart J 148(5): 776-782.
17. Hamm CW, Giannitsis E, Katus HA (2002) Cardiac troponin elevations in patients without acute coronary syndrome. Circulation 106(23): 2871-2872.
18. Pateron D, Beyne P, Laperche T et al (1999) Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 29(3): 640-643.
19. Parekh NK, Hynan LS, De Lemos J, Lee WM (2007) Elevated troponin I levels in acute liver failure: is myocardial injury an integral part of acute liver failure? Hepatology 45(6): 1489-1495.
20. Henriksen JH, Gotze JP, Fuglsang S et al (2003) Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52(10): 1511-1517.
21. Yildiz R, Yildirim B, Karincaoglu M et al (2005) Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol 20(7): 1115-1120.
22. Raedle-Hurst TM, Welsch C, Forestier N et al (2008) Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. Eur J Gastroenterol Hepatol 20(9): 865-873.
23. Garrison RN, Cryer HM, Howard DA, Polk HC Jr (1984) Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 199(6): 648-655.
24. Mansour A, Watson W, Shayani V, Pickleman J (1997) Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 122(4): 730-735; discussion 5-6.
25. Csikesz NG, Nguyen LN, Tseng JF, Shah SA (2009) Nationwide volume and mortality after elective surgery in cirrhotic patients. J Am Coll Surg 208(1): 96-103.
26. Pugh RN, Murray-Lyon IM, Dawson JL et al (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8): 646-649.
27. Lin CH, Lin FY, Wang SS et al (2005) Cardiac surgery in patients with liver cirrhosis. Ann Thorac Surg 79(5): 1551-1554.
28. Filsoufi F, Salzberg SP, Rahmanian PB et al (2007) Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl 13(7): 990-995.
29. An Y, Xiao YB, Zhong QJ (2007) Open-heart surgery in patients with liver cirrhosis: indications, risk factors, and clinical outcomes. Eur Surg Res 39(2): 67-74.
30. Klemperer JD, Ko W, Krieger KH et al (1998) Cardiac operations in patients with cirrhosis. Ann Thorac Surg 65(1): 85-87.
31. Nishi H, Takahashi T, Ichikawa H et al (2009) Prediction of postoperative hepatic dysfunction after cardiac surgery in patients with chronic congestive heart failure. Gen Thorac Cardiovasc Surg 57(7): 357-362.
32. Malinchoc M, Kamath PS, Gordon FD et al (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31(4): 864-871.
33. Wiesner R, Edwards E, Freeman R et al (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124(1): 91-96.
34. Northup PG, Wanamaker RC, Lee VD et al (2005) Model for end-stage liver disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg 242(2): 244-251.
35. Befeler AS, Palmer DE, Hoffman M et al (2005) The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to child-turcotte-pugh classification in predicting outcome. Arch Surg 140(7): 650-654; discussion 5.
36. Teh SH, Nagorney DM, Stevens SR et al (2007) Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology 132(4): 1261-1219.
37. Ailawadi G, Lapar DJ, Swenson BR et al (2009) Model for end-stage liver disease predicts mortality for tricuspid valve surgery. Ann Thorac Surg 87(5): 1460-1467; discussion 7-8.
38. Morisaki A, Hosono M, Sasaki Y et al (2010) Risk factor analysis in patients with liver cirrhosis undergoing cardiovascular operations. Ann Thorac Surg 89(3): 811-817.
39. Matthews JC, Pagani FD, Haft JW et al (2010) Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation 121(2): 214-220.
40. Thielmann M, Mechmet A, Neuhauser M et al (2010) Risk prediction and outcomes in patients with liver cirrhosis undergoing open-heart surgery. Eur J Cardiothorac Surg DOI 10. 1016/j. ejcts. 2010. 02. 042.
41. Fuhrmann V, Jager B, Zubkova A, Drolz A (2010) Hypoxic hepatitis - epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 122(5-6): 129-139.
42. Ebert EC (2006) Hypoxic liver injury. Mayo Clin Proc 81(9): 1232-1236.
43. Henrion J, Schapira M, Luwaert R et al (2003) Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 82(6): 392-406.
44. Birrer R, Takuda Y, Takara T (2007) Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 46(14): 1063-1070.
45. Fuhrmann V, Kneidinger N, Herkner H et al (2009) Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 35(8): 1397-1405.
46. Denis C, De Kerguennec C, Bernuau J et al (2004) Acute hypoxic hepatitis ('liver shock'): still a frequently overlooked cardiological diagnosis. Eur J Heart Fail 6(5): 561-565.
47. Bechmann LP, Jochum C, Kocabayoglu P et al (2010) Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol 53(4): 639-647.
48. Allen LA, Felker GM, Pocock S et al (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the candesartan in heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 11(2): 170-177.
49. Gore RM, Mathieu DG, White EM et al (1994) Passive hepatic congestion: cross-sectional imaging features. AJR Am J Roentgenol 162(1): 71-75.
50. Kubo SH, Walter BA, John DH et al (1987) Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 147(7): 1227-1230.
51. Lau GT, Tan HC, Kritharides L (2002) Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 90(12): 1405-1409.
52. Batin P, Wickens M, McEntegart D et al (1995) The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 16(11): 1613-1618.
53. Whitfield JB (2001) Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38(4): 263-355.
54. Paolicchi A, Emdin M, Ghliozeni E et al (2004) Images in cardiovascular medicine. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation 109(11): 1440.
55. Emdin M, Pompella A, Paolicchi A (2005) Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 112(14): 2078-2080.
56. Paolicchi A, Minotti G, Tonarelli P et al (1999) Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation - a potential mechanism in atherosclerosis. J Investig Med 47(3): 151-160.
57. Wannamethee G, Ebrahim S, Shaper AG (1995) Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 142(7): 699-708.
58. Kazemi-Shirazi L, Endler G, Winkler S et al (2007) Gamma-glutamyltransferase and long-term survival: is it just the liver? Clin Chem 53(5): 940-946.
59. Ruttmann E, Brant LJ, Concin H et al (2005) Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163, 944 Austrian adults Circulation 112(14): 2130-2137.
60. Lee DS, Evans JC, Robins SJ et al (2007) Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham heart study. Arterioscler Thromb Vasc Biol 27(1): 127-133.
61. Ulus T, Yildirir A, Sade LE et al (2008) Serum gamma-glutamyl transferase activity: new high-risk criteria in acute coronary syndrome patients? Coron Artery Dis 19(7): 489-495.
62. Lee DH, Silventoinen K, Hu G et al (2006) Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28, 838 middle-aged men and women. Eur Heart J 27(18): 2170-2176.
63. Emdin M, Passino C, Michelassi C et al (2009) Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol 136(1): 80-85.
64. Chang Y, Ryu S, Sung E, Jang Y (2007) Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem 53(4): 686-692.
65. Goessling W, Massaro JM, Vasan RS et al (2008) Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135(6): 1935-1944, 44 e1.
66. Oda E, Kawai R, Watanabe K, Sukumaran V (2009) Prevalence of metabolic syndrome increases with the increase in blood levels of gamma glutamyltransferase and alanine aminotransferase in Japanese men and women. Intern Med 48(16): 1343-1350.
67. Olynyk JK, Knuiman MW, Divitini ML et al (2009) Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 104(7): 1715-1722.
68. Abdou AS, Magour GM, Mahmoud MM (2009) Evaluation of some markers of subclinical atherosclerosis in Egyptian young adult males with abdominal obesity. Br J Biomed Sci 66(3): 143-147.
69. Selden MA, Helzberg JH, Waeckerle JF et al (2009) Elevated alanine aminotransferase in current national football league players: correlation with cardiometabolic syndrome markers, obesity, and insulin resistance. South Med J 102(10): 1003-1006.
70. Kim SK, Kim DJ, Kim SH et al (2010) Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis. Diabetes Res Clin Pract 88(1): 111-116.
71. Wang CC, Lin SK, Tseng YF et al (2009) Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 24(8): 1411-1416.
72. Yun KE, Shin CY, Yoon YS, Park HS (2009) Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 205(2): 533-537.
73. Schindhelm RK, Dekker JM, Nijpels G et al (2007) Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191(2): 391-396.
74. Ruhl CE, Everhart JE (2009) Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 136(2): 477-485 e11.